%20%20(%20Pixa.jpg)
.jpg)
LATEST NEWS
February 2023
-
All links were checked and are working properly.
-
Clinical trial numbers were updated accordingly.
January 2023
-
All links were checked and working properly except the Arasena A prescription link. The Arasena A link https://www.nlm.nih.gov/pubs/techbull/ja22/ja22_pubchem.html was updated December 16th, and no longer shows the prescribing information. It has been updated to https://www.gnhindia.com/products/nz-drugs/vira-a-solution-for-infusion-200-mg-ml/.
-
Clinical trial numbers were updated accordingly.
© 2021-2023 Marine Pharmacology
December 2022
-
All the links have been checked and were working properly, except links addressing compounds in Chinese clinical trials. We are working with Dr. Jinbo Yang's group to update these links.
-
The approved marine-derived pharmaceutical Belantamab Mafoditin-blmf (Blenrep) withdrawal process was initiated on 11-22-2022, following the request of the FDA. The agency's request was based on the previously announced outcome of the Phase III DREAMM-3 confirmatory trial, which did not meet the requirements of the FDA accelerated approval regulations. (https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-blenrep-us-marketing-authorisation/).
October 2022
-
All the links have been checked and were working properly.
-
The number of current clinical trials was updated accordingly.
September 2022
-
Copyright notices were posted on the top and bottom of this page.
-
All the links have been checked and were working properly.
-
The approved marine-derived pharmaceutical Panobinostat (Farydak) was withdrawn on 3-24-2022, and a notice was issued by the Federal Register was added to the webpage (https://www.federalregister.gov/documents/2022/03/24/2022-06182/secura-bio-inc-withdrawal-of-approval-of-new-drug-application-for-farydak-panobinostat-capsules-10).